Similar articles

• Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?

  Briasoulis E, Fatouros M, Roukos DH. Briasoulis E, et al. Ann Surg Oncol. 2007 Oct;14(10):2691-5. doi: 10.1245/s10434-007-9358-z. Epub 2007 Jul 26. Ann Surg Oncol. 2007. PMID: 17653806 No abstract available.
• Gastro-oesophageal junction: to FLOT or to CROSS?

  van den Ende T, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, van Laarhoven HWM. van den Ende T, et al. Acta Oncol. 2020 Feb;59(2):233-236. doi: 10.1080/0284186X.2019.1698765. Epub 2019 Dec 9. Acta Oncol. 2020. PMID: 31813320 No abstract available.
• The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer.

  Kurokawa Y, Sasako M. Kurokawa Y, et al. Surg Oncol Clin N Am. 2017 Apr;26(2):213-224. doi: 10.1016/j.soc.2016.10.011. Surg Oncol Clin N Am. 2017. PMID: 28279465 Review.
• Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.

  Molina R, Lamarca A, Martínez-Amores B, Gutiérrez A, Blázquez A, López A, Granell J, Álvarez-Mon M. Molina R, et al. Eur J Surg Oncol. 2013 Aug;39(8):814-22. doi: 10.1016/j.ejso.2013.05.003. Epub 2013 Jun 5. Eur J Surg Oncol. 2013. PMID: 23755989
• Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.

  Ajani JA, Fairweather J, Pisters PW, Charnsangavej C. Ajani JA, et al. Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):19-21. Oncology (Williston Park). 2000. PMID: 11200143 Review.